CSI Market
Sign In | Register

Htg Molecular Diagnostics Inc (HTGM) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access HTGM Annual Cash Flow →
The data below summarizes Htg Molecular Diagnostics Inc's cash flow activity from Mar 31 2022 to Mar 31 2023, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2023)
3 Months 		(Dec 31 2022) (Sep 30 2022) (Jun 30 2022) (Mar 31 2022)
Operating Activities
Income-5.05
Depreciation & amortization0.09
Amortization of Other Assets0.07
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.42
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.13
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Accretion Of Discount-
Bad Debt Recoveries Net-
Amortization Of Term Loan Deferred Financing Costs-
Amortization Of Discount On Term Loan-
Amortization Of Premium On Term Loan-
Amortization Of Discount On Convertible Notes-
Change In Redeemable Convertible Preferred Stock Warrant Liability-
Accretion Of Incentive From Landlord-
Amortization Of Convertible Note Discount And Issuance Costs-
Amortization Of Convertible Note Issuance Costs-
Employee Stock Purchase Plan Expense0.01
Amortization Of Operating Lease Right Of Use Assets-
Non Cash Operating Lease Expense0.11
Accrued Interest On Available For Sale Securities Investments-0.03
Accretion Of Discount On Long Term Obligation-
Accretion Of Interest On Long Term Obligation0.00
Increase Decrease In Operating Lease Liabilities-0.12
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.29
Increase (Decrease) in Accounts Payable-0.03
Increase (Decrease) in Accrued Liabilities-0.57
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.28
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.04
Discontinued operations0.00
Net Cash flow from Operating Activities-4.36
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities0.00
Payments to Acquire Available-for-sale Securities, Debt-3.54
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-3.54
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.15
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.16
Payments Of Deferred Convertible Note Financing Costs-
Proceeds From Term Loan-
Payments From Settlement Of Fractional Common Shares-
Stock Issued During Period Exercise Of Warrant Value-
Temporary Equity Accretion To Redemption Value-
Proceeds From Stock Purchased Under Employee Stock Purchase Plan-
Proceeds From Issuance Of Common Stock Net Of Other Offering Expenses Paid And Payable-
Credit Facility Lender Fees-
Taxes Paid For Net Share Settlement Of Restricted Stock Awards0.00
Payments Of Deferred Offering Costs-
Finance Lease Principal Payments0.00
Proceeds From Issuance Of S V B Term Loan And Common Stock Warrants-
Proceeds From Issuance Of S V B Term Loan-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-1.31
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-4.37
Total Cash Flow-9.21
4 historic quarters locked

Sign in to unlock the full Htg Molecular Diagnostics Inc cash flow history.

Sign In Create Free Account

About Htg Molecular Diagnostics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-020725

Figures are derived from filed reports and may be restated. Historical data is subject to revision.